New combo therapy aims to save rectal cancer Patients' anus
NCT ID NCT05215379
First seen Jan 05, 2026 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tested whether adding immunotherapy to standard chemoradiation helps patients with ultra-low rectal cancer achieve a complete response and avoid surgery. 201 adults with tumors within 5 cm of the anal edge who wanted to preserve their anus participated. The goal was to improve cancer control and increase the chance of organ preservation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Colorectal Surgery in Changhai Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.